Alpha-L-fucosidase as a marker for liver cancer
Author Information
Author(s): S. Bukofzer, P.M. Stass, M.C. Kew, M. de Beer, H.T. Groeneveld
Primary Institution: Witwatersrand University Medical School and Johannesburg Hospital
Hypothesis
Is alpha-L-fucosidase a reliable serum marker for hepatocellular carcinoma compared to alpha-fetoprotein?
Conclusion
Alpha-L-fucosidase is less useful than alpha-fetoprotein as a single marker for hepatocellular carcinoma, but they can be used together to improve diagnostic accuracy.
Supporting Evidence
- Alpha-L-fucosidase levels were significantly higher in patients with hepatocellular carcinoma compared to those with benign liver diseases.
- Alpha-fetoprotein was found to be more sensitive and specific than alpha-L-fucosidase.
- Using both markers together reduced the number of false-negative results for alpha-fetoprotein.
Takeaway
Doctors tested a blood marker called alpha-L-fucosidase to see if it could help find liver cancer, but found that another marker, alpha-fetoprotein, works better on its own.
Methodology
The study compared serum levels of alpha-L-fucosidase and alpha-fetoprotein in patients with hepatocellular carcinoma and benign liver diseases.
Limitations
The study was limited to southern African blacks and may not be generalizable to other populations.
Participant Demographics
72 southern African blacks with hepatocellular carcinoma and 64 matched patients with benign hepatic diseases.
Statistical Information
P-Value
0.0001
Statistical Significance
p=0.0001
Want to read the original?
Access the complete publication on the publisher's website